Why the study?
Despite widespread use of risk indices like the Framingham Risk Score and standard preventive therapies, CVD remains the leading cause of mortality worldwide due to substantial residual disease.
Design
Review
Answers are grounded in this paper and cite their sources.
Persistent CVD burden demands clinical vigilance; leaves open whether AI proteomics meaningfully advances risk assessment.
Cardiovascular disease (CVD) diagnosis, risk stratification, and treatment have improved significantly since the landmark Framingham Heart Study first defined key risk factors 50 years ago [1]. However, widespread use of indices such as the Framingham Risk Score (FRS) to guide patient management has not altered CVD status as the leading cause of mortality worldwide (still contributing to 1 in every 3 deaths in developed countries). This high burden of CVD persists due to the substantial amount of residual disease despite the use of anti-lipid, anti-hypertensive and anti-diabetic drugs for primary and secondary preventions.
No takes yet. Share an insight, caveat, or question.
Siu Kwan Sze (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: